Asset profile
Lumateperone · Caplyta
Small molecule
Evidence outlook
Approved: Major Depressive Disorder, Schizophrenia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
118 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 117 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Lumateperone (Caplyta): this drug | Approved | Small molecule | Serotonin 5-HT2A / dopamine D1-D2 receptor | ||
| Risperidone (Risperdal) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist), Serotonin 5-HT2A / dopamine D1-D2 receptor | ||
| Aripiprazole (Abilify Maintena) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist) | ||
| Aripiprazole (Abilify MyCite) | Approved | Combination | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist) | ||
| Aripiprazole (Abilify) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Aripiprazole Lauroxil (Aristada Initio) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Aripiprazole Lauroxil (Aristada) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Asenapine | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Brexpiprazole (Rexulti) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Cariprazine (Vraylar) | Approved | Small molecule | Dopamine D3/D2 receptor (partial agonist) | ||
| Clozapine | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Cyclobenzaprine (Tonmya) | Approved | Small molecule | 5-HT2A, α1-adrenergic, H1-histaminergic, and M1-muscarinic acetylcholine receptors (functional antagonism) | ||
| Dexmedetomidine (Igalmi) | Approved | — | — | ||
| Dexmedetomidine (Igalmi) | Approved | Small molecule | Alpha-2 adrenergic receptor (agonist) | ||
| Dextromethorphan / Bupropion (Auvelity) | Approved | Small molecule | sigma-1/NMDA | ||
| Esketamine (Spravato) | Approved | Small molecule | NMDA receptor |
…and 103 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(14 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (2)
2027 (5)
March 2027 (1)
What to watch
April 2027 (1)
What to watch
June 2027 (2)
July 2027 (1)
What to watch
2028 (3)
January 2028 (2)
June 2028 (1)
What to watch
2029 (1)
September 2029 (1)
What to watch
2030 (1)
January 2030 (1)
What to watch
2031 (1)
October 2031 (1)
What to watch
2032 (1)
April 2032 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.